呼吸系統領域相關聯盟及授權合約 (2016～2024年)

本報告審查了 2016 年至 2024 年期間與呼吸設備相關的 415 份合作夥伴關係和許可協議，並審查了交易總數、金融交易條款以及交易活躍度最高的 25 家公司的趨勢。合約文件等

主要優點

該報告為讀者提供了以下主要好處：

• 了解 2016 年以來的合約趨勢
• 查看業務夥伴交易
• 基準分析：確定交易的市場價值
• 財務狀況
• 交易清單：按公司名稱 (A-Z)、治療領域和技術類型
• 主要交易（金額基礎）
• 最活躍的談判者
• 每筆交易的資產識別和交易條件
• 取得合約文件：深入了解交易結構
• 盡職調查：評估擬議交易條款對合作夥伴公司的適用性
• 節省數百小時的研究時間

合約分析允許盡職調查：

• 授予/選擇了哪些權利？
• 合約授予了哪些權利？
• 授予哪些類型的專有權？
• 合約的付款結構為
• 如何審核銷售和付款？
• 合約期限為
• 合約的主要條款是如何定義的？
• 如何對待和擁有知識產權？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密和發布？
• 如何解決爭議？
• 什麼情況下可以取消合約？
• 如果所有者發生變化會怎樣？
• 已就哪些從屬許可或分包條款達成協議？
• 公司需要哪些樣板條款？
• 哪些樣板條款看起來有所不同，取決於合作夥伴和交易類型？
• 每家公司對契約法主張哪一個管轄權？

目錄

摘要整理

第1章 簡介

第2章 呼吸系統的交易趨勢

• 呼吸系統相關的交易:年度轉變
• 呼吸系統相關的交易:各交易類型
• 呼吸系統相關的交易:各產品部門
• 呼吸系統相關的交易:各開發階段
• 呼吸系統相關的交易:各技術類型
• 呼吸系統相關的交易:各適應症

第3章 呼吸系統領域的交易:金錢的交易條件

• 財務條件的明確指示
• 標題額
• 預付款金
• 里程碑
• 特許權使用費率

第4章 與呼吸系統領域的交易:主要客戶交易

• 交易最活躍的談判者
• 交易最活躍的談判者清單
• 主要交易:各交易金額

第5章 呼吸系統領域的交易:契約文件名錄

• 契約文件:可取得的事項

第6章 按呼吸系統領域的交易:治療標的

• 呼吸系統交易：依治療目標分類
• 交易目錄
• 交易目錄：依公司劃分（2016-2024 年）
• 貿易名錄：依技術類型分類（2016-2024 年）
• 交易類型的定義
• 關於生物製藥研究股份有限公司
• 目前的合作關係
• 當前合約
• Current Partnering 最近的報告標題

Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 415 respiratory deals from 2016 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of respiratory dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in respiratory dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the respiratory field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in respiratory dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of respiratory deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of respiratory deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in respiratory deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Respiratory Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse respiratory collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Respiratory Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of respiratory trends and structure of deals entered into by leading biopharma companies worldwide.

Respiratory Collaboration and Licensing Deals includes:

• Trends in respiratory dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of respiratory deal records covering pharmaceutical and biotechnology
• The leading respiratory deals by value
• Most active respiratory licensing dealmakers

In Respiratory Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Respiratory Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in respiratory dealmaking

• 2.1. Introduction
• 2.2. Respiratory partnering over the years
• 2.3. Respiratory partnering by deal type
• 2.4. Respiratory partnering by industry sector
• 2.5. Respiratory partnering by stage of development
• 2.6. Respiratory partnering by technology type
• 2.7. Respiratory partnering by therapeutic indication

Chapter 3 - Financial deal terms for respiratory partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for respiratory partnering
• 3.3. Respiratory partnering headline values
• 3.4. Respiratory deal upfront payments
• 3.5. Respiratory deal milestone payments
• 3.6. Respiratory royalty rates

Chapter 4 - Leading respiratory deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in respiratory partnering
• 4.3. List of most active dealmakers in respiratory
• 4.4. Top respiratory deals by value

Chapter 5 - Respiratory contract document directory

• 5.1. Introduction
• 5.2. Respiratory partnering deals where contract document available

Chapter 6 - Respiratory dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by respiratory therapeutic target
• Deal directory
• Deal directory - Respiratory deals by company A-Z 2016 to 2024
• Deal directory - Respiratory deals by technology type 2016 to 2024
• Deal type definitions
• About Bioharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Respiratory partnering since 2016
• Figure 2: Respiratory partnering by deal type since 2016
• Figure 3: Respiratory partnering by industry sector since 2016
• Figure 4: Respiratory partnering by stage of development since 2016
• Figure 5: Respiratory partnering by technology type since 2016
• Figure 6: Respiratory partnering by indication since 2016
• Figure 7: Respiratory deals with a headline value
• Figure 8: Respiratory deals with upfront payment values
• Figure 9: Respiratory deals with milestone payment
• Figure 10: Respiratory deals with royalty rates
• Figure 11: Active respiratory dealmaking activity since 2016
• Figure 12: Top respiratory deals by value since 2016